Key result
Thymopetidum added to regular therapy for 3 months improved cardiac function and ameliorated T-helper transcription factor polarization compared to regular therapy alone in aging men with chronic cardiac insufficiency.
Why the study?
Does thymopetidum added to regular therapy improve cardiac function and immune marker profiles in aging male patients with chronic cardiac insufficiency?
Does thymopetidum added to regular therapy improve cardiac function and immune marker profiles in aging male patients with chronic cardiac insufficiency?
Immune modulation with thymopetidum may improve cardiac function and ameliorate T-helper cell and cytokine imbalances in aging male patients with chronic cardiac insufficiency.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for thymopetidum in chronic cardiac insufficiency; should not change practice without randomized confirmation.
AIM: The aim of this study was to explore the role of immune modulation therapy in regulating the imbalance of Th1/Th2, serum IFN-γ, IL-4 and the T-cell-specific transcription factors T-bet/GATA-3 in peripheral blood in aging male patients with chronic cardiac insufficiency (CCI). PATIENTS & METHODS: In total, 156 participants were divided into three groups: the CCI intervention group, which received regular therapy and thymopetidum (20 mg intramuscular injection, once every other day for 3 months; n = 70), the CCI control group, which received regular therapy (n = 56) and 50 healthy individuals older than 57 years of age, who served as normal controls. RESULTS: Before therapy, in comparison with the control group, levels of left ventricular end diastolic diameter, NT-proBNP, C-reactive protein (CRP), Th1, Th1/Th2, IFN-γ, and T-bet mRNA and T-bet/GATA-3 mRNA all increased, and the level of left ventricular ejection fraction (LVEF), 6MWT, Th2, IL-4, and GATA-3 mRNA also decreased in both the CCI intervention and control groups. Linear correlation analysis indicated that LVEF was inversely correlated with serum NT-proBNP, CRP, Th1/Th2, IFN-γ and T-bet mRNA/GATA-3 mRNA, and was positively correlated with plasma IL-4. After 3 months of therapy, levels of left ventricular end diastolic diameter, NT-proBNP, CRP, Th1, Th1/Th2, IFN-γ, T-bet mRNA and T-bet/GATA-3 mRNA decreased in the two CCI subgroups, but levels in the CCI intervention group were lower in comparison to the control group. Levels of LVEF, 6MWT, Th2 and GATA-3 mRNA increased in the two CCI subgroups, while levels in the CCI intervention group were higher in comparison with the control group. Plasma levels of IL-4 showed no change after treatment. CONCLUSION: Immune modulation improved cardiac function of CCI patients and was associated with amelioration of T-helper superficial transcription factor polarization and its related cytokine imbalance. Immune modulation might be a new treatment strategy for aging CCI patients.
No takes yet. Share an insight, caveat, or question.
Han et al. (2013) studied Chronic cardiac insufficiency (n=156). Thymopetidum vs. Regular therapy alone was evaluated on Cardiac function (LVEF, left ventricular end diastolic diameter, NT-proBNP, 6MWT) and T-bet/GATA-3 gene expression. Thymopetidum added to regular therapy for 3 months improved cardiac function and ameliorated T-helper transcription factor polarization compared to regular therapy alone in aging men with chronic cardiac insufficiency.
Synapse has enriched 10 related papers. Consider them for comparative context: